An analyst from Anand Rathi said that Bank of Maharashtra continues to exhibit a positive technical structure and the stock ...

The segment of privacy coins outperforms the broader cryptocurrency market, with a roughly 290% rise in 2025. The rising user ...

Indicators highlighted a marked improvement in buying momentum, with the price successfully breaking through the moving average ...

Broader markets are also showing signs of strain. This widespread deterioration highlights a clear contraction in risk ...

Discover how to use the upside/downside ratio, a key market breadth indicator, to analyze advancing and declining volumes on ...

The market is likely to consolidate further with a negative bias. Below are some short-term trading ideas to consider on ...

Acura has announced a new compact SUV model, the ADX. Set to make its debut this spring with a competitive starting price of $35,000, the SUV is positioned as the brand’s entry-level offering and aims ...

Somer G. Anderson is CPA, doctor of accounting, and an accounting and finance professor who has been working in the accounting and finance industries for more than 20 years. Her expertise covers a ...

Bank of America said one of its contrarian indicators is close to flashing a sell signal. The bank's Bull & Bear Indicator is hovering just under an "extreme bullish" reading. The indicator recently ...

HIGHS Competitive level of standard content, reasonably priced, responsive handling. LOWS Weak powertrain fails the willing chassis, no hybrid option, interior needs more premium materials to be a ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...